Fineline Cube

Follow:
14433 Articles
Shanghai Pharmaceuticals and Baxter China Forge Strategic Partnership for Anesthesia Products
CompanyDeals

Shanghai Pharmaceuticals and Baxter China Forge Strategic Partnership for Anesthesia Products

CARsgen Therapeutics Reports 2025 Interim Results and Regulatory Progress
Company

CARsgen Therapeutics Reports 2025 Interim Results and Regulatory Progress

Superluminal Collaborates With Eli Lilly on Small Molecule Therapeutics for Cardiometabolic Diseases
CompanyDeals

Superluminal Collaborates With Eli Lilly on Small Molecule Therapeutics for Cardiometabolic Diseases

Sanofi's Rilzabrutinib Granted Orphan Drug Designation for IgG4-Related Disease by EMA
CompanyDrug

Sanofi’s Rilzabrutinib Granted Orphan Drug Designation for IgG4-Related Disease by EMA

China's NHSA Releases Interim Measures for Medical Case-Based Payment Management
Policy / Regulatory

China’s NHSA Releases Interim Measures for Medical Case-Based Payment Management

Pfizer's Emblaveo Prescribed in Shanghai Hospitals for First Time Nationwide
CompanyDrug

Pfizer’s Emblaveo Prescribed in Shanghai Hospitals for First Time Nationwide

Insilico Medicine's ISM8969 Nears Clinical Evaluation for Parkinson's Disease
CompanyDrug

Insilico Medicine’s ISM8969 Nears Clinical Evaluation for Parkinson’s Disease

SineuGene's First-in-Class ALS Gene Therapy SNUG01 Gets NMPA Clinical Trial Clearance
CompanyDrug

SineuGene’s First-in-Class ALS Gene Therapy SNUG01 Gets NMPA Clinical Trial Clearance

Fosun Pharma Issues China's First Private Pharma Innovation Bond to Accelerate R&D
CompanyDeals

Fosun Pharma Issues China’s First Private Pharma Innovation Bond to Accelerate R&D

Lilly Hikes Mounjaro Price in UK by 170% for Private-Pay Patients
CompanyDrug

Eli Lilly Hikes Mounjaro Price in UK by 170% for Private-Pay Patients

Qihan Biotech's QT-019B Gains FDA IND Approval for Autoimmune Diseases
CompanyDrug

Qihan Biotech’s QT-019B Gains FDA IND Approval for Autoimmune Diseases

Novartis' Ianalumab Shows Positive Results in Phase 3 Trials for ITP and Sjögren's Disease
CompanyDrug

Novartis’ Ianalumab Shows Positive Results in Phase 3 Trials for ITP and Sjögren’s Disease